My understanding was that the commercialization company will "purchase" Leronlimab at 50% market price (and they get their 50% profit by selling it). Of course, you might be right and they will get a discount, the question would be then: the commercialization royalty to CYDY is on the market price or discounted price (if there is a discount)?. We will know when the deal is finalized.
Your point is valid: we need very few patients to reach profitability, depending on the initial label this will happen soon. Let's don't forget that the label will likely be extended when the drug probes itself in the market (and, more importantly when the doctors and patients learn is out there).
And then, the flood gates will be opened with Mono ….